Namely, we assessed drug sensitivity in an expanded panel of 19 breast cancer cell lines and also looked for independent evidence of PTEN-SSL activity in the form of mutual exclusivity of mutations in large tumor cohorts. This evidence concerns the gene PTEN and breast carcinoma.